The fund seeks long-term capital growth by investing primarily in equities of companies outside Canada and the United States.
Is this fund right for you?
- Investors who are looking for an international equity fund to hold as part of their portfolio
- Want a medium-to long-term investment
- Can handle the volatility of stock markets
Risk Rating
How is the fund invested?
(as of July 31, 2025)
Asset allocation (%)
|
Name |
Percent |
|
International Equity |
98.6 |
|
Cash and Equivalents |
1.4 |
Geographic allocation (%)
|
Name |
Percent |
|
Ireland |
22.1 |
|
France |
12.6 |
|
Switzerland |
9.7 |
|
Japan |
7.5 |
|
Denmark |
6.0 |
|
Thailand |
5.5 |
|
Korea, Republic Of |
5.1 |
|
United Kingdom |
5.1 |
|
Germany |
4.9 |
|
Other |
21.5 |
Sector allocation (%)
|
Name |
Percent |
|
Healthcare |
24.0 |
|
Financial Services |
15.8 |
|
Industrial Goods |
15.6 |
|
Consumer Goods |
13.9 |
|
Technology |
13.2 |
|
Energy |
6.1 |
|
Industrial Services |
3.6 |
|
Real Estate |
3.3 |
|
Telecommunications |
2.4 |
|
Other |
2.1 |
Growth of $10,000
(since inception)
Data not available based on date of inception
Fund details
(as of July 31, 2025)
Top holdings |
% |
Samsung Electronics Co Ltd |
5.1 |
Legrand SA |
4.2 |
Taiwan Semiconductor Manufactrg Co Ltd - ADR |
3.8 |
Steris PLC |
3.7 |
Roche Holding AG - Partcptn |
3.7 |
Ryanair Holdings PLC - ADR |
3.6 |
Crh PLC |
3.6 |
Thai Beverage PCL |
3.6 |
Dcc PLC |
3.5 |
Deutsche Boerse AG Cl N |
3.5 |
Total allocation in top holdings |
38.3 |
Portfolio characteristics |
|
Standard deviation |
10.2% |
Dividend yield |
2.6% |
Yield to maturity |
- |
Duration (years) |
- |
Coupon |
- |
Average credit rating |
Not rated |
Average market cap (million) |
$170,429.2 |
Understanding returns
Annual compound returns (%)
1 MO |
3 MO |
YTD |
1 YR |
{{snapShot.Return1Mth|customNumber:1}} | {{snapShot.Return3Mth|customNumber:1}} | {{snapShot.ReturnYTD|customNumber:1}} | {{snapShot.Return1Yr|customNumber:1}} |
3 YR |
5 YR |
10 YR |
INCEPTION |
{{snapShot.Return3Yr|customNumber:1}} | {{snapShot.Return5Yr|customNumber:1}} | {{snapShot.Return10Yr|customNumber:1}} | {{snapShot.ReturnInception|customNumber:1}} |
Calendar year returns (%)
2024 |
2023 |
2022 |
2021 |
{{snapShot.Return1YrCalendar|customNumber:1}} | {{snapShot.Return2YrCalendar|customNumber:1}} | {{snapShot.Return3YrCalendar|customNumber:1}} | {{snapShot.Return4YrCalendar|customNumber:1}} |
2020 |
2019 |
2018 |
2017 |
{{snapShot.Return5YrCalendar|customNumber:1}} | {{snapShot.Return6YrCalendar|customNumber:1}} | {{snapShot.Return7YrCalendar|customNumber:1}} | {{snapShot.Return8YrCalendar|customNumber:1}} |
Range of returns over five years
(November 1, 2018 - September 30, 2025)
Best return |
Best period end date |
Worst return |
Worst period end date |
9.8% |
Sept. 2025 |
0.9% |
Oct. 2023 |
Average return |
% of periods with positive returns |
Number of positive periods |
Number of negative periods |
5.3% |
100.0% |
24 |
0 |
Q2 2025 Fund Commentary
Market commentary
EAFE equities rose during the second quarter of 2025. The threat of economic disruption because of tariff conflicts declined as investors regained confidence in the strength of the U.S. consumer. In Europe, a new German Chancellor was appointed, with a mandate to increase fiscal stimulus. China continued to combat slow growth and deflationary dynamics in its local economy.
Performance
The Fund’s relative exposure to Ryanair Holdings PLC, Bank Leumi Le Israel BM and Taiwan Semiconductor Manufacturing Co. Ltd. had a positive impact on performance. Relative exposure to Sanofi SA, Coloplast AS and Alcon Inc. was negative for performance.
Currency effects had the most positive impact on the Fund’s performance. Stock selection in health care and consumer staples had a negative impact on performance.
Portfolio activity
0
Outlook
The sub-advisor favours attractively valued EAFE companies whose performance is not driven by macroeconomic events.